Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.

Publications

Putting the “Specific” Back in Specific Jurisdiction: The Importance of Claim-by-Claim Jurisdictional Analysis in a Post-BMS Landscape

January 2018 - Drug & Device Law Blog

Publications

Putting the “Specific” Back in Specific Jurisdiction: The Importance of Claim-by-Claim Jurisdictional Analysis in a Post-BMS Landscape

January 2018 - Drug & Device Law Blog

In Bristol-Myers Squibb Co. v. Superior Court, 137 S. Ct. 1773 (2017) (“BMS”), the United States Supreme Court concluded that specific jurisdiction must be premised on a defendant’s in-state conduct giving rise to a plaintiff’s alleged injury. The Court explained that plaintiffs therefore could not pursue their claims in a state in which they did not reside or in which they were not injured if a defendant conducted no activity in that state connected to the injury. That other in-state plaintiffs may be advancing similar claims as part of a coordinated proceeding did nothing to change this analysis.

Click here to read the blog post.

Authors

Related News

COVID-19 and Ivermectin Lawsuits

DeAngelo A. LaVette, Nathan P. Nasrallah, published in American Bar Association, Section of Litigation, Mass Torts Litigation More